Predictive Oncology Inc. POAI
Apr 21, 2026, 3:59 PM EDT
52-week range unavailable
- YTD
- +498.78%
- 1 year
- +520.73%
- Market cap
- 4.57M
- Revenue (ttm)
- 1.75M
- Shares out
- 6.67M
- Forward P/E
- -5.72
- YTD return
- +498.78%
- 1-year return
- +520.73%
- Volume
- 19.09K
- Open
- 4.49
- Previous close
- 4.91
- Day's range
- 4.21 – 4.98
- Beta
- 1.15
2Y -38.45 (-86.60%)
Key statistics
- Enterprise value
- 2.77M
- PEG ratio
- 0.00
- Price / sales
- 2.62
- Price / book
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -43.10%
- Free cash flow
- -7.75M
- Total cash
- 5.33M
- Total debt
- 2.70M
- Return on equity
- -149.36%
- Short % of float
- 2.27%
- 50-day average
- 0.73052
- 200-day average
- 1.21
Analyst view
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.32 | -0.36 | -0.04 | -12.50% |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.68 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.04 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.85 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.78 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.95 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 19, 2024 | HC Wainwright & Co. | init | — | Buy |
About Predictive Oncology Inc.
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- predictive-oncology.com
News
Predictive Oncology Q2 Earnings Call Highlights 
Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened 
Predictive Oncology Q4 Earnings Call Highlights 
Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened 
Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison 
Financial Analysis: Predictive Oncology (NASDAQ:POAI) and Healthcare Triangle (NASDAQ:HCTI) 
Why RF Industries Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket 
Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened 
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure 
Predictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks Transcript
Your note
Sign in to keep a note on POAI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHUNG-WELCH NANCY | Director | Stock Award(Grant) | Apr 4, 2024 | 21,237 |
| HANDLEY DANIEL E | Director | Stock Award(Grant) | Apr 4, 2024 | 18,661 |
| HAWRYLUK MATTHEW | Director | Stock Award(Grant) | Apr 4, 2024 | 9,488 |
| MYERS ROBERT L | Chief Financial Officer | Conversion of Exercise of derivative security | Sep 24, 2023 | 4,720 |
| NUZUM CHARLES LEE SR | Director | Stock Award(Grant) | Apr 4, 2024 | 31,921 |
| RAO VEENA | Director | Stock Award(Grant) | Apr 4, 2024 | 9,117 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.07% | 71,307 | 48.92K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.78% | 51,868 | 35.58K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.22% | 14,948 | 10.25K | Sep 29, 2024 |
| State Street Corporation | 0.21% | 13,837 | 9.49K | Sep 29, 2024 |
| Csenge Advisory Group | 0.19% | 13,000 | 8.92K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.19% | 12,560 | 8.62K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.05% | 69,881 | 47.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.52% | 34,894 | 23.94K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 9,279 | 6.37K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 3,782 | 2.59K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 2,138 | 1.47K | Oct 30, 2024 |